News | December 16, 2009

PET Better Identifies Malignant Breast Tumors

FDG-PET breast cancer patient.

December 17, 2009 - Positron emission tomography (PET) scans used with an agent called 64Cu-TP3805 may significantly contribute to the management of breast cancer, reducing the number of biopsies.

Scientists from the Kimmel Cancer Center at Jefferson have discovered a possible way for malignant breast tumors to be identified, without the need for a biopsy, according to findings published online in the Journal of Nuclear Medicine.

Because current imaging modalities miss up to 30 percent of breast cancers and cannot distinguish malignant tumors from benign tumors, which leads to biopsies, approximately 5.6 million biopsies performed in the United States find only benign lesions.

To better identify malignant tumors, Mathew Thakur, Ph.D., professor of Radiology at Jefferson Medical College of Thomas Jefferson University and director of Radiopharmaceutical Research and Nuclear Medicine Research conducted a study using an imaging agent to target a specific biomarker that visualizes malignant breast lesions early and reliably.

An agent called 64Cu-TP3805, which is used to evaluate tumors via PET imaging. 64Cu-TP3805 detects breast cancer by finding a biomarker called VPAC1, which is overexpressed as the tumor develops.

The researchers compared the images using that agent with images using the "gold standard" imaging agent, 18F-FDG. They used MMTVneu mice, which are mice that develop breast tumors spontaneously, like humans. The mice first received a PET scan using the 18F-FDG. Then they received a CT scan, and then they received another PET scan using 64Cu-TP3805.

Ten tumors were detected on the mice. Four tumors were detected using both 18F-FDG and 64Cu-TP3805, and four additional tumors were found with 64Cu-TP3805 only. All eight of these tumors overexpressed the VPAC1 oncogene on tumor cells and were malignant by histology. The remaining two tumors were benign and were detected only with 18F-FDG. They did not express the VPAC1 oncogene, and thus were not detected by the 64Cu-TP3805.

According to Dr. Thakur, if 64Cu-TP3805 is equally as effective in humans, then he believes PET scans with 64Cu-TP3805 will significantly contribute to the management of breast cancer.

For more information: www.snm.org

Related Content

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Women With Coronary Artery Wall Thickness at Risk for Heart Disease
News | Cardiac Imaging | April 25, 2019
The thickness of the coronary artery wall as measured by magnetic resonance imaging (MRI) is an independent marker for...
Cianna Medical featured its wire-free marker system on the exhibit floor of the breast imaging symposium in Hollywood, Fla.

Cianna Medical featured its wire-free marker system on the exhibit floor of the breast imaging symposium in Hollywood, Fla.

Feature | Breast Imaging | April 24, 2019 | By Greg Freiherr
Wires have traditionally been placed prior to lumpectomy to mark cancerous tissues in the breast.
GE Healthcare showcases Senographe Pristina with its add-on-biopsy kit at the breast imaging symposium

GE Healthcare showcases Senographe Pristina with its add-on-biopsy kit at the breast imaging symposium in Hollywood, Florida. Photo by Greg Freiherr

Feature | Breast Imaging | April 23, 2019 | By Greg Freiherr
Signs of what the future may look like in women’s health dotted the exhibit floor of the...
In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...